Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4

References

• [No authors listed]Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative GroupCirculation199897220222129631869
   PubMed Web of Science ®Google Scholar
• BakerWLColemanCIKlugerJSystematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart diseaseAnn Intern Med200915186187120008762
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKøberLLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative GroupLancet20003551575158110821360
   PubMed Web of Science ®Google Scholar
• [No authors listed]Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study InvestigatorsLancet200035525325910675071
   PubMed Web of Science ®Google Scholar
• FoxKMEURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet200336278278813678872
   PubMed Web of Science ®Google Scholar
• Vande Werf FBaxJBetriuAESC Committee for Practice GuidelinesManagement of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of CardiologyEur Heart J2008292909294519004841
   PubMed Web of Science ®Google Scholar
• AntmanEMAnbeDTArmstrongPWACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction)J Am Coll Cardiol200444E1E21115358047
   PubMedGoogle Scholar
• FoxKGarciaMAArdissinoDTask Force on the Management of Stable Angina Pectoris of the European Society of CardiologyESC Committee for Practice Guidelines (CPG)Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of CardiologyEur Heart J2006271341138116735367
   PubMed Web of Science ®Google Scholar
• López-SendónJSwedbergKMcMurrayJTask Force on ACE-inhibitors of the European Society of CardiologyExpert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of CardiologyEur Heart J2004251454147015302105
   PubMed Web of Science ®Google Scholar
• KupersmithJHolmes-RovnerMHoganARovnerDGardinerJCost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmiasProg Cardiovasc Dis1995373073467871179
   PubMed Web of Science ®Google Scholar
• ReederCEGourleyGAWurtzbacherJDReedPThe impact of angiotensin-converting enzyme inhibitors on managed care: economic, clinical, and humanistic outcomesAm J Manag Care20006Suppl 3S112S12810977441
   PubMed Web of Science ®Google Scholar
• DavieAPACE inhibitors after myocardial infarction. Clinical and economic considerationsPharmacoeconomics20001723724310947299
   PubMed Web of Science ®Google Scholar
• FidanDUnalBCritchleyJCapewellSEconomic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000–2010QJM200710027728917449875
   PubMed Web of Science ®Google Scholar
• McMurrayJJMcGuireADavieAPHughesDCost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarctionEur Heart J199718141114159458446
   PubMed Web of Science ®Google Scholar
• LePenCLilliuHKellerTFiessingerSThe economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunctionPharmacoeconomics199814495810182194
   PubMed Web of Science ®Google Scholar
• LamyAYusufSPogueJGafniAHeart Outcomes Prevention Evaluation InvestigatorsCost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) studyCirculation200310796096512600907
   PubMed Web of Science ®Google Scholar
• BriggsAMihaylovaBSculpherMEUROPA Trial InvestigatorsCost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA studyHeart2007931081108617135223
   PubMed Web of Science ®Google Scholar
• BozcaliEDedeogluDBKarpuzVSuzerOKarpuzHCardioprotective effects of zofenopril, enalapril and valsartan against ischaemia/reperfusion injury as well as doxorubicin cardiotoxicityActa Cardiol201267879622455094
   PubMed Web of Science ®Google Scholar
• Gómez-RosoMMonteroMJCarrónRSevillaMACardiovascular changes in spontaneously hypertensive rats are improved by chronic treatment with zofenoprilBr J Pharmacol20091581911192119917062
   PubMed Web of Science ®Google Scholar
• EvangelistaSManziniSAntioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenoprilJ Int Med Res200533425415651714
   PubMed Web of Science ®Google Scholar
• PrzyklenkKKlonerRA“Cardioprotection” by ACE-inhibitors in acute myocardial ischemia and infarction?Basic Res Cardiol199388Suppl 11391548357329
   PubMed Web of Science ®Google Scholar
• AmbrosioniEDefining the role of zofenopril in the management of hypertension and ischemic heart disordersAm J Cardiovasc Drugs20077172417355163
   PubMed Web of Science ®Google Scholar
• BorghiCBacchelliSDegli EspostiDAmbrosioniEA review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseasesExpert Opin Pharmacother200451965197715330734
   PubMed Web of Science ®Google Scholar
• BorghiCAmbrosioniENovoSVinereanuDAmbrosioGSMILE-4 Working PartyComparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4)Clin Cardiol20123541642322707187
   PubMed Web of Science ®Google Scholar
• Diagnosis-Related Groups in Europe: Towards Efficiency and Quality Available from: http://www.eurodrg.eu/Accessed April 8, 2013
   Google Scholar
• CookRJSackettDLThe number needed to treat: a clinically useful measure of treatment effectBMJ19953104525447873954
   PubMed Web of Science ®Google Scholar
• SimoensSHealth economic assessment: a methodological primerInt J Environ Res Public Health200962950296620049237
   PubMed Web of Science ®Google Scholar
• GoldMRSiegelJERusselLBWeinsteinMCCost-Effectiveness in Health and MedicineNew York, NYOxford University Press1996
   Google Scholar
• DrummondMFO’BrienBStoddartGLTorranceGWMethods for the Economic Evaluation of Health Care Programmes2nd edOxford, UKOxford Medical Publication1997
   Google Scholar
• GrieveAPIssues for statisticians in pharmaco-economic evaluationsStat Med199817171517239749442
   PubMed Web of Science ®Google Scholar
• MartinSRiceNSmithPCDoes health care spending improve health outcomes? Evidence from English programme budgeting dataJ Health Econ20082782684218261812
   PubMed Web of Science ®Google Scholar
• BraithwaiteRSMentorSMIdentifying favorable-value cardiovascular health servicesAm J Manag Care20111743143821756013
   PubMed Web of Science ®Google Scholar
• VieiraRDHuebWHlatkyMCost-effectiveness analysis for surgical, angioplasty, or medical therapeutics for coronary artery disease: 5-year follow-up of Medicine, Angioplasty, or Surgery Study (MASS) II TrialCirculation201212611 Suppl 1S145S15022965975
   PubMed Web of Science ®Google Scholar
• LiuYDalalKReview of cost-effectiveness analysis of medical treatment for myocardial infarctionInt J Prev Med20112647221603010
   PubMedGoogle Scholar
• GorenoiVSchönermarkMPHagenAPercutaneous coronary intervention with optimal medical therapy versus. optimal medical therapy alone for patients with stable angina pectorisGMS Health Technol Assess20117 Doc07
   Google Scholar
• HillRABolandADicksonRDrug-eluting stents: a systematic review and economic evaluationHealth Technol Assess200711iiixi22117999841
   PubMed Web of Science ®Google Scholar
• MantovaniLGBelisariASzucsTDCaptopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in ItalyPharmacol Res1998373453519642029
   PubMed Web of Science ®Google Scholar
• HummelSPiercyJWrightRDavieABagustAMcMurrayJAn economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United KingdomPharmacoeconomics1997122 Pt 118219210169670
   PubMed Web of Science ®Google Scholar
• MichelBCAlMJRemmeWJEconomic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The NetherlandsEur Heart J1996177317408737104
   PubMed Web of Science ®Google Scholar
• TsevatJDukeDGoldmanLCost-effectiveness of captopril therapy after myocardial infarctionJ Am Coll Cardiol1995269149197560617
   PubMed Web of Science ®Google Scholar
• FranzosiMGMaggioniAPSantoroETognoniGCavalieriECost-effectiveness analysis of early lisinopril use in patients with acute myocardial infarction. Results from GISSI-3 trialPharmacoeconomics19981333734610178659
   PubMed Web of Science ®Google Scholar
• CapriSPerliniSCost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular eventsCurr Med Res Opin20052191392116003858
   PubMed Web of Science ®Google Scholar
• SchädlichPKBrechtJGRangoonwalaBHuppertzECost effectiveness of ramipril in patients at high risk for cardiovascular events:economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspectivePharmacoeconomics20042295597315449961
   PubMed Web of Science ®Google Scholar
• AurbachARussWBattegayECost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspectiveSwiss Med Wkly200413439940515389357
   PubMed Web of Science ®Google Scholar
• SmithMGNevilleAMMiddletonJCClinical and economic benefits of ramipril: an Australian analysis of the HOPE studyIntern Med J20033341441914511193
   PubMed Web of Science ®Google Scholar
• HartWMRubio-TerrésCMargaletFernández IGonzálezJuanateyJRCost-effectiveness analysis of ramipril treatment of patients at high-risk of cardiovascular events in SpainAn Med Interna200219515520 Spain12481494
   PubMedGoogle Scholar
• BjörholtIAnderssonFLKahanTOstergrenJThe cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE studyJ Intern Med200225150851712028506
   PubMed Web of Science ®Google Scholar
• MalikISBhatiaVKKoonerJSCost effectiveness of ramipril treatment for cardiovascular risk reductionHeart20018553954311303006
   PubMed Web of Science ®Google Scholar
• HartWMRubio-TerresCPajueloFGonzález JuanateyJRCost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE studyEur J Heart Fail2002455355812167396
   PubMed Web of Science ®Google Scholar
• SchädlichPKHuppertzEBrechtJGCost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health InsurancePharmacoeconomics19981465366910346417
   PubMed Web of Science ®Google Scholar
• ErhardtLBallSAnderssonFBergentoftPMartinezCCost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril EfficacyPharmacoeconomics1997122 Pt 225626610170450
   PubMed Web of Science ®Google Scholar